CRISPR Therapeutics appoints Brendan Smith as CFO; Michael Tomsicek retires

CRISPR Therapeutics AG

Brendan Smith named SVP & CFO effective Oct 14, 2021; succeeds Michael Tomsicek who retired.
Smith previously CFO at Translate Bio (acquired by Sanofi for $3.2B) and partner at BCG.
Smith receives $435K base salary, 40% bonus target, 90K options and 15K RSUs with standard vesting.
Tomsicek to remain in advisory role through Dec 31, 2021; his departure not due to any accounting disagreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brendan Smith

Senior Vice President and Chief Financial Officer

CRSP · CRISPR Therapeutics AG

Effective: 2021-10-14
Filed: October 14, 2021, 7:59 PM ET

On October 14, 2021, CRISPR Therapeutics AG (the “Company”) announced the hiring and appointment of Brendan Smith as its Senior Vice President and Chief Financial Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brendan Smith was appointed as Senior Vice President and Chief Financial Officer at CRISPR Therapeutics AG.

Action: appointed
Role: Senior Vice President and Chief Financial Officer

Exact text from the filing

On October 14, 2021, CRISPR Therapeutics AG (the “Company”) announced the hiring and appointment of Brendan Smith as its Senior Vice President and Chief Financial Officer, effective immediately.

View on SEC.gov

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0001193125-21-298277

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.